• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Policy

CDC gives $12m to states to fight opioid epidemic

July 18, 2017 By Sarah Faulkner

CDC

The Centers for Disease Control and Prevention said today that it plans to award more than $12 million this week to 23 states and the District of Columbia to support their efforts in tackling the opioid overdose epidemic. The funding comes from the fiscal year 2017 omnibus appropriations bill that became law in May. States […]

Filed Under: Featured, Funding Roundup, Pain Management, Pharmaceuticals, Policy Tagged With: Centers for Disease Control & Prevention

CDC chief propped up controversial anti-aging medicine in private practice

July 17, 2017 By Sarah Faulkner

CDC

Before the newly-appointed CDC head Dr. Brenda Fitzgerald ran the public health department for the state of Georgia, she was a board-certified OB/GYN with a private practice. But according to a report from Forbes, she not only provided women’s healthcare in the 30 years she practiced medicine – she was also a fellow in “anti-aging medicine.” […]

Filed Under: Featured, Hospital Care, Pharmaceuticals, Policy, Women's Health Tagged With: Centers for Disease Control & Prevention

NY Rep. Collins loses millions on Innate flop

June 28, 2017 By Sarah Faulkner

Innate Immunotherapeutics

Earlier this year, Rep. Chris Collins’ (R-NY) 16.8% stake in Innate Immunotherapeutics (ASX:IIL) was worth $45.5 million. But since the Australian biotech’s lead drug failed in a 93-patient trial this week, shares in the company dropped to 4¢ apiece and Collins’ holdings are now valued at just $1.5 million. As the company’s largest investor and […]

Filed Under: Clinical Trials, Featured, Immunotherapy, Pharmaceuticals, Policy, Wall Street Beat Tagged With: innateimmunotherapeutics

Mylan shareholders vote against executive pay package, but re-elect board

June 22, 2017 By Sarah Faulkner

Mylan

At the company’s annual meeting, Mylan (NSDQ:MYL) shareholders re-elected the drugmaker’s board despite a campaign spearheaded by major investors to do otherwise. The campaign hoped to encourage shareholders to vote down most of the board’s directors in response to Mylan’s drug pricing practices for its EpiPen device. The influential proxy advisory firm, ISS, also urged shareholders […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Mylan, Sanofi-Aventis

Nevada law takes aim at insulin makers and their pricing strategies

June 20, 2017 By Sarah Faulkner

Pills

Nevada passed a law last week instituting new reporting requirements for drug makers that manufacture insulin. Other states like New York and Maryland have also established requirements that pharmaceutical companies report price increases on certain drugs. The law, S.B. 539, mandates that the Nevada Dept. of Health & Human Services make a list of prescription […]

Filed Under: Featured, Pharmaceuticals, Policy Tagged With: Capitol Hill

Senate drug price hearing turns into debate over healthcare reform

June 19, 2017 By Sarah Faulkner

Prescription drugs

Members of the Senate Health, Education, Labor and Pensions committee gathered last week to discuss the rising costs of prescription drugs. But the hearing quickly morphed into a heated back-and-forth between senators over the Republican’s efforts to reform healthcare. Democratic senators, including Sens. Patty Murray (D-Wash.) and Chris Murphy (D-Conn.), used their time to criticize […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Gilead Sciences

Report: Mylan may have overcharged US by $1.3B for EpiPen

May 31, 2017 By Sarah Faulkner

Prescription drugs

Mylan (NSDQ:MYL) shares dipped slightly in mid-afternoon trading today after Sen. Chuck Grassley’s (R-Iowa) office released a Health and Human Services estimate claiming that taxpayers overpaid by as much as $1.27 billion for Mylan’s EpiPen device from 2006 to 2016. The charges stem from Mylan’s decision to classify the emergency allergy auto-injector as a generic, instead of […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Mylan

Mallinckrodt faces probe over price hikes for injectable pain-killer

May 30, 2017 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Sen. Claire McCaskill (D-Mo.) penned a letter to Mallinckrodt Pharmaceuticals (NYSE:MNK) last week, probing for details about the company’s pricing strategies for its injectable pain-killer, Ofirmev. Mallinckrodt acquired Ofirmev in 2014, when it bought Cadence Pharmaceuticals in a $1.4 billion deal. In May of that year, Mallinckrodt hiked the pain-killer’s list price from $14.75 per vial to […]

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Mallinckrodt Pharmaceuticals

FDA chief: Changing generics regulations could reel in drug prices

May 25, 2017 By Sarah Faulkner

FDA

Part of the FDA commissioner’s job is to oversee the federal regulatory watchdog as it evaluates pharmaceuticals for safety and efficacy. Most FDA chiefs have avoided the topic of drug prices, given that it isn’t a clearly-stated part of the agency’s mission But just 2 weeks into the job, newly-confirmed FDA commish Dr. Scott Gottlieb proposed […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy Tagged With: Mylan

UK watchdog accuses Merck of restricting biosimilar competition

May 23, 2017 By Sarah Faulkner

Merck

Britain’s Competition and Markets Authority accused Merck‘s (NYSE:MRK) European unit, Merck Sharp & Dohme, of conducting an unfair discount scheme that it said was designed to restrict competition from biosimilar copies of the company’s drug, Remicade. Remicade is an antibody drug used to treat rheumatoid arthritis, ulcerative colitis and Chron’s disease. It was the 1st […]

Filed Under: Featured, Pharmaceuticals, Policy, Regulatory/Compliance, Wall Street Beat Tagged With: johnsonandjohnson, Merck

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Interim pages omitted …
  • Go to page 8
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS